In 2020, 8,722 monthly prescriptions for GLP-1 agonists were written for adolescents between ages 12 and 17 and young adults aged 18 to 25, according to an analysis of a database that tracks about 94% of prescriptions filled at retail pharmacies
Increased synovitis and angiogenesis are related to oxidative stress induced by hypoxia (Biniecka et al., 2010)
Afamelanotide (MT1, sold as Scenesse) received EMA approval in 2014 and FDA approval in 2019 for erythropoietic protoporphyria
This is the core driver behind the GLP-1 boom among consumers looking for better control of their weight by suppressing appetite or reducing food noise. Pet owners who have seen the benefits of GLP-1 drugs like Ozempic and Wegovy are now wondering if the same can be done for their pets
[3] However, in a promising transition for all metabolic health stakeholders, the treatment landscape is likely to drastically shift with generic GLP-1 receptor agonists (GLP-RAs) becoming available in India for the first time, marking a meaningful change in access for a class that was, until recently, out of reach for most patients
Mol Plant-Microbe Interact 21(5):507517 Ancheeva E, Daletos G, Proksch P (2020) Bioactive secondary metabolites from endophytic fungi